As a caveat, however, CTLA-4 inhibitors as single-agent therapy in recent phase 2 studies of metastatic uveal melanoma have shown an equally unimpressive 0% ORR, with significant grade 3–4 toxicities in approximately 35% of cases [27,37]. This evidence concerns the gene CTLA4 and uveal melanoma.